Provided by Tiger Fintech (Singapore) Pte. Ltd.

Prevail Therapeutics

23.00
+0.0000
Volume:- -
Turnover:- -
Market Cap:158.09M
PE:-9.96
High:23.00
Open:23.00
Low:23.00
Close:23.00
Loading ...

Company Profile

Company Name:
Prevail Therapeutics
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.